Quest Partners LLC Takes $34,000 Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Quest Partners LLC purchased a new position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 4,182 shares of the company’s stock, valued at approximately $34,000.

A number of other large investors have also recently bought and sold shares of the business. Nisa Investment Advisors LLC grew its position in Health Catalyst by 461.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after buying an additional 5,232 shares during the last quarter. Quarry LP grew its stake in shares of Health Catalyst by 59.4% during the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after purchasing an additional 2,610 shares during the period. nVerses Capital LLC purchased a new position in shares of Health Catalyst in the 3rd quarter valued at about $59,000. Perfromance Wealth Partners LLC acquired a new stake in shares of Health Catalyst during the 2nd quarter valued at approximately $64,000. Finally, Mackenzie Financial Corp purchased a new position in Health Catalyst in the 2nd quarter valued at approximately $70,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $8.83 on Monday. The company has a market capitalization of $537.29 million, a price-to-earnings ratio of -6.54 and a beta of 1.32. Health Catalyst, Inc. has a 1-year low of $5.42 and a 1-year high of $11.41. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The stock’s fifty day simple moving average is $8.12 and its 200-day simple moving average is $7.33.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same quarter in the prior year, the company posted ($0.22) EPS. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. On average, sell-side analysts predict that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Daniel Lesueur sold 8,137 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total value of $61,678.46. Following the sale, the chief operating officer now owns 140,108 shares of the company’s stock, valued at $1,062,018.64. The trade was a 5.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now directly owns 255,881 shares in the company, valued at approximately $1,847,460.82. This represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,068 shares of company stock worth $257,555 in the last ninety days. Insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Stephens raised their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Citigroup raised their target price on shares of Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Evercore ISI boosted their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Finally, Royal Bank of Canada increased their target price on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Health Catalyst currently has an average rating of “Moderate Buy” and a consensus target price of $11.79.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.